LifeVantage Co. (NASDAQ:LFVN) Short Interest Down 5.4% in December

LifeVantage Co. (NASDAQ:LFVN - Get Free Report) was the recipient of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 191,800 shares, a drop of 5.4% from the December 15th total of 202,800 shares. Currently, 1.9% of the company's stock are sold short. Based on an average daily trading volume, of 110,600 shares, the short-interest ratio is currently 1.7 days.

LifeVantage Trading Up 0.0 %

Shares of LFVN stock traded up $0.01 during trading on Friday, reaching $25.31. 134,842 shares of the company's stock traded hands, compared to its average volume of 112,642. LifeVantage has a 1 year low of $5.22 and a 1 year high of $27.38. The firm's 50-day moving average is $16.74 and its 200 day moving average is $12.16. The company has a market capitalization of $316.88 million, a P/E ratio of 79.10 and a beta of 0.82.

LifeVantage (NASDAQ:LFVN - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.15 EPS for the quarter, meeting the consensus estimate of $0.15. The firm had revenue of $47.21 million during the quarter. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%.

LifeVantage Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were paid a $0.04 dividend. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.63%. LifeVantage's dividend payout ratio (DPR) is 50.00%.

Institutional Investors Weigh In On LifeVantage

Institutional investors have recently bought and sold shares of the stock. Ritholtz Wealth Management raised its stake in shares of LifeVantage by 62.0% during the third quarter. Ritholtz Wealth Management now owns 28,666 shares of the company's stock valued at $346,000 after acquiring an additional 10,974 shares during the last quarter. Barclays PLC lifted its holdings in LifeVantage by 38.2% in the 3rd quarter. Barclays PLC now owns 41,966 shares of the company's stock worth $507,000 after buying an additional 11,608 shares during the period. HighTower Advisors LLC bought a new stake in shares of LifeVantage in the 3rd quarter worth approximately $638,000. Capital Management Corp VA purchased a new position in shares of LifeVantage during the third quarter valued at approximately $5,073,000. Finally, Renaissance Technologies LLC lifted its stake in LifeVantage by 2.1% in the second quarter. Renaissance Technologies LLC now owns 855,118 shares of the company's stock worth $5,490,000 after acquiring an additional 17,300 shares during the period. 35.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LFVN. Lake Street Capital assumed coverage on shares of LifeVantage in a report on Thursday, December 19th. They set a "buy" rating and a $26.00 price objective for the company. Craig Hallum started coverage on LifeVantage in a research report on Tuesday, January 14th. They issued a "buy" rating and a $35.00 target price for the company.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.